Search

Your search keyword '"Chinot, O."' showing total 543 results
Start Over Author "Chinot, O."
543 results on '"Chinot, O."'

2. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

Author

Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., and Soussain, C.

Published
2019
Full Text
View/download PDF

3. Innovative treatments for meningiomas

Author

Graillon, T., primary, Tabouret, E., additional, Salgues, B., additional, Horowitz, T., additional, Padovani, L., additional, Appay, R., additional, Farah, K., additional, Dufour, H., additional, Régis, J., additional, Guedj, E., additional, Barlier, A., additional, and Chinot, O., additional

Published
2023
Full Text
View/download PDF

5. Molecular and clinical diversity in primary central nervous system lymphoma

Author

Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Göttingen (UMG), Freie Universität Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Imagerie moléculaire et thérapies innovantes en oncologie (IMOTION), Université de Bordeaux (UB), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Hôpitaux Civils de Colmar, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Institut Bergonié [Bordeaux], UNICANCER, Sorbonne Université (SU), Centre Hospitalier Saint Jean de Perpignan, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut Curie - Saint Cloud (ICSC), DESSAIVRE, Louise, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Anatomie Pathologique [CHRU Nancy], and École pratique des hautes études (EPHE)

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Oncology, tumor heterogeneity, Hematology, multi-omics, microenvironment, PCNSL, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity.To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data.Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue.The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.

Published
2023

7. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Author

Gao, Y., Weenink, B., van den Bent, M.J., Erdem-Eraslan, L., Kros, J.M., Sillevis Smitt, PAE, Hoang-Xuan, K., Brandes, A.A., Vos, M., Dhermain, F., Enting, R., Ryan, G.F., Chinot, O., Ben Hassel, M., van Linde, M.E., Mason, W.P., Gijtenbeek, J.M.M., Balana, C., von Deimling, A., Gorlia, Th, Stupp, R., Hegi, M.E., Baumert, B.G., and French, P.J.

Published
2018
Full Text
View/download PDF

12. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

Author

Coomans, M., Dirven, L., Aaronson, N., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Taphoorn, M.J.B., EORTC Quality Life Grp, EORTC Brain Tumor Grp, Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neuro-Oncologie [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), University of Zurich, Neurology, CCA - Cancer Treatment and quality of life, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
REHABILITATION, Cancer Research, [SDV]Life Sciences [q-bio], BEVACIZUMAB, EUROPEAN-ORGANIZATION, 610 Medicine & health, LOMUSTINE, time-to-deterioration, SDG 3 - Good Health and Well-being, CRITERIA, Humans, brain tumor, deterioration-free-survival, progressive disease, Cancer och onkologi, Brain Neoplasms, TEMOZOLOMIDE, Glioma, Progression-Free Survival, humanities, 10040 Clinic for Neurology, ANAPLASTIC OLIGODENDROGLIOMA, Oncology, Cancer and Oncology, PHASE-II, Quality of Life, TRIAL, Neurology (clinical), RESPONSE ASSESSMENT
Abstract

Background Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. Methods We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. Results Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9–29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8–5.4 months, and median time-to-deterioration between 8.2–11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. Conclusions HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients’ functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.

Published
2022

17. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study

Author

Houillier, Caroline, Dureau, S, Taillandier, Luc, Houot, Roch, Chinot, O., Molucon-Chabrot, Cécile, Schmitt, Anna, Gressin, Rémy, Choquet, Sylvain, Damaj, Gandhi, Peyrade, Frédéric, Abraham, Julie, Delwail, V, Gyan, Emmanuel, Sanhes, Laurence, Cornillon, Jerome, Garidi, Reda, Delmer, Alain, Al Jijakli, Ahmad, Morel, Pierre, Waultier, Agathe, Paillassa, Jérôme, Chauchet, A, Gastinne, Thomas, Laadhari, Mouna, Plissonnier, Anne-Sophie, Feuvret, Loïc, Cassoux, Nathalie, Touitou, Valerie, Ricard, Jean-Damien, Hoang-Xuan, Khe, Soussain, Carole, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Curie [Paris], Centre Hospitalier Universitaire de Nancy (CHU Nancy), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Louise Michel [Clermont-Ferrand], CHU Clermont-Ferrand, Institut Bergonié [Bordeaux], UNICANCER, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Amiens-Picardie, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), CHU Limoges, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Saint Jean de Perpignan, Institut de Cancérologie Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier de Lens, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital d'instruction des Armées Percy, Service de Santé des Armées, Immunité et cancer (U932), and Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Cancer Research, Adolescent, Lymphoma, [SDV]Life Sciences [q-bio], Hematopoietic Stem Cell Transplantation, Middle Aged, Transplantation, Autologous, Combined Modality Therapy, Central Nervous System Neoplasms, Young Adult, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Recurrence, Local
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported the results of a randomized phase II study in patients with newly diagnosed primary CNS lymphoma (age 18-60 years). Patients were treated with high-dose methotrexate-based induction chemotherapy followed by whole-brain radiotherapy (WBRT) or high-dose chemotherapy (thiotepa-busulfan-cyclophosphamide) with autologous stem-cell transplantation (ASCT). The median follow-up was 33 months. In this report, we provide long-term data (median follow-up, 8 years) regarding the outcomes and toxicities. Fifty-three and 44 patients received induction chemotherapy followed by WBRT or ASCT, respectively. Their 8-year event-free survival from random assignment was 67% and 39% in the ASCT and WBRT arms, respectively ( P = .03), with a significantly lower risk of relapse after ASCT (hazard ratio, 0.13; P < .001). One third of patients who relapsed after WBRT were alive after salvage treatment. Five and four patients died of ASCT and WBRT-related toxicities, respectively. The 8-year overall survival was 69% and 65% in the ASCT and WBRT arms, respectively (not significant). Balance (52% v 10%, P ≤ 0.001) and neurocognition (64% v 13%, P < .001) significantly deteriorated after WBRT compared with ASCT during the follow-up. This study shows that 40 Gy WBRT should be avoided in first-line treatment because of its neurotoxicity and suboptimal efficacy in reducing relapses while ASCT appears to be highly efficient in preventing relapses.

Published
2022

18. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Author

Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., Schott, R., Honnorat, J., Fabbro, M., Tennevet, I., Ghiringhelli, F., Guillamo, J.S., Durando, X., Castera, D., Frenay, M., Campello, C., Dalban, C., Skrzypski, J., and Chinot, O.

Published
2014
Full Text
View/download PDF

21. High-grade glioma in elderly patients: can the oncogeriatrician help?

Author

Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, and Rousseau F

Subjects
brain tumor, older cancer patient, chemotherapy toxicity, oncogeriatric charter, Geriatrics, RC952-954.6
Abstract

Emeline Tabouret,1 Louis Tassy,2 Olivier Chinot,1 ElodieCrétel,3 Frederique Retornaz,4 Frederique Rousseau5 1Department of Neuro-oncology, Timone Hospital, Marseille, France; 2Department of Medical Oncology, Centre Léon Bérard, Lyon, France; 3Transveral Oncogeriatric Unit, University Hospital Timone, Marseille, France; 4Departmental Gerontologic Center, Marseille, France; 5Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France Abstract: Gliomas are the most frequent primary brain tumors in adults. As the population ages in Western countries, the number of people being diagnosed with glioblastoma is expected to increase. Clinical management of elderly patients with primary brain tumors is difficult, owing to multiple comorbidities, polypharmacy, decreased tolerance to chemotherapy, and an increased risk of radiation-induced neurotoxicity. A few specific randomized studies have shown a benefit for radiotherapy in elderly patients with good performance status. For patients with poor performance status, chemotherapy (temozolomide) has been shown to be associated with prolonged duration of response. Patients with methylated O6-alkylguanine deoxyribonucleic acid alkyltransferase promoter seem to have better outcomes. Oncogeriatrics proposes the geriatric evaluation of elderly patients to improve therapeutic choices and optimize the management of treatment toxicities and comorbidities. Keywords: brain tumor, older cancer patient, chemotherapy toxicity, oncogeriatric charter

Published
2013

22. Surgical management

Author

Sawamura, Y., de Tribolet, N., Régis, J., Chinot, O., Bouillot, P., Dufour, H., Peragut, J. C., Sawamura, Yutaka, editor, Shirato, Hiroki, editor, and de Tribolet, Nicolas, editor

Published
1998
Full Text
View/download PDF

24. P04.08 Biopsy-only glioblastoma (BO-GBM) as a heterogeneous group of patients

Author

Harlay, V, primary, Loundou, A, additional, Boucard, C, additional, Petrirena, G, additional, Barrie, M, additional, Campello, C, additional, Autran, D, additional, Padovani, L, additional, Figarella, D, additional, Boissonneau, S, additional, Dufour, H, additional, Baumstarck, K, additional, Tabouret, E, additional, and Chinot, O, additional

Published
2021
Full Text
View/download PDF

25. PL03.1.A Surgery for glioblastomas in the elderly: an ANOCEF trial (CSA)

Author

Laigle-Donadey, F, primary, Metellus, P, additional, Guyotat, J, additional, Menei, P, additional, Proust, F, additional, Dufour, H, additional, Chinot, O, additional, Honnorat, J, additional, Faillot, T, additional, Paquis, P, additional, Peruzzi, P, additional, Emery, E, additional, Guillamo, J S, additional, Carpentier, A, additional, Wager, M, additional, Lebbah, S, additional, Hajage, D, additional, Delattre, J Y, additional, and Cornu, P, additional

Published
2021
Full Text
View/download PDF

26. KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI)

Author

Ducray, F, primary, Sanson, M, additional, Chinot, O, additional, Fontanilles, M, additional, Rivoirard, R, additional, Thomas-Maisonneuve, L, additional, Cartalat, S, additional, Tabouret, E, additional, Bonneville-Levard, A, additional, Darlix, A, additional, Ameli, R, additional, Meyronet, D, additional, Gueyffier, F, additional, Remontet, L, additional, Maucort-Boulch, D, additional, Dehais, C, additional, and Honnorat, J, additional

Published
2021
Full Text
View/download PDF

27. P11.04 Autonomy duration as analyzed by KPS≥70 cumulative time in patients with biopsy-only glioblastoma (BO-GBM). A sub-analysis of the Timone cohort

Author

Harlay, V, primary, Loundou, A, additional, Boucard, C, additional, Petrirena, G, additional, Barrie, M, additional, Campello, C, additional, Autran, D, additional, Padovani, L, additional, Figarella, D, additional, Boissonneau, S, additional, Dufour, H, additional, Baumstarck, K, additional, Tabouret, E, additional, and Chinot, O, additional

Published
2021
Full Text
View/download PDF

28. PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period

Author

Coomans, M, primary, Dirven, L, additional, Aaronson, N, additional, Baumert, B, additional, van den Bent, M, additional, Bottomley, A, additional, Brandes, A, additional, Chinot, O, additional, Coens, C, additional, Gorlia, T, additional, Herrlinger, U, additional, Keime-Guibert, F, additional, Malmström, A, additional, Martinelli, F, additional, Stupp, R, additional, Talacchi, A, additional, Wick, W, additional, Reijneveld, J, additional, and Taphoorn, M, additional

Published
2021
Full Text
View/download PDF

34. Measuring change in health-related quality of life

Author

Coomans, M.B., Taphoorn, M.J.B., Aaronson, N.K., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Dirven, L., EORTC Quality Life Grp, EORTC Brain Tumor Grp, Neurology, CCA - Cancer Treatment and quality of life, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
0301 basic medicine, medicine.medical_specialty, BEVACIZUMAB, Medicine (miscellaneous), patient-reported outcome, VALIDATION, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, Clinical decision making, law, medicine, AcademicSubjects/MED00300, Sjukgymnastik, Group level, Physiotherapy, Change score, Health related quality of life, business.industry, brain tumor, quality of life, questionnaire, Original Articles, Editor's Choice, 030104 developmental biology, 030220 oncology & carcinogenesis, Scale (social sciences), Physical therapy, Patient-reported outcome, AcademicSubjects/MED00310, business
Abstract

Background Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions. Methods HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project). Change in HRQoL scores, measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN20 questionnaires, was analyzed in 3 ways: (1) at the group level, comparing mean changes in scale/item scores between treatment arms, (2) at the patient level per scale/item, calculating the percentage of patients that deteriorated, improved, or remained stable per scale/item, and (3) at the individual patient level, combining all scales/items. Results Baseline and first follow-up HRQoL data were available for 3727 patients. At the group scale/item level, only the item “hair loss” showed a significant and clinically relevant change (ie, ≥10 points) over time, whereas change scores on the other scales/items were statistically significant only (all P Conclusions Different analytical methods of changes in HRQoL result in distinct conclusions of treatment effects, all of which may be relevant for informing clinical decision making.

Published
2020

43. Épendymomes intracrâniens de l'adulte. Diagnostic histologique et facteurs histopronostiques

Author

Figarella-Branger, D., Metellus, P., Barrié, M., Maues de Paula, A., Fernandez, C., Polivka, M., Vital, A., Labrousse, F., Vignaud, J.-M., Laquerrière, A., Rousselet, M.-C., Lacroix, C., Saikali, S., Chapon, F., Gontier, M.-F., Chrétien, F., Babin, P., Rigau, V., Vandenbos, F., Peoc'h, M., Kujas, M., Chinot, O., Gouvernet, J., Giorgi, R., Guyotat, J., and Jouvet, A.

Published
2007
Full Text
View/download PDF

46. Joint SFMN/ANOCEF focus on 18F-FDOPA PET imaging in glioma: Current applications and perspectives

Author

Verger, A., primary, Kas, A., additional, Darcourt, J., additional, Chinot, O., additional, Taillandier, L., additional, Hoang Xuan, K., additional, Guedj, E., additional, Bouvet, C., additional, Bund, C., additional, Habert, M.-O., additional, Isal, S., additional, Kotzki, P.-O., additional, Lejeune, F., additional, Namer, I., additional, Pallardy, A., additional, Payoux, P., additional, Prunier, C., additional, Ribeiro, M., additional, Semah, F., additional, and Verger, A., additional

Published
2020
Full Text
View/download PDF

47. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study

Author

Montégut, C., primary, Guillamo, J.-S., additional, Ducray, F., additional, Dehais, C., additional, Chinot, O., additional, Cohen-Jonathan Moyal, E.L., additional, Le Rhun, E., additional, Loiseau, H., additional, Appay, R., additional, Figarella-Branger, D., additional, Delattre, J.-Y., additional, and Tabouret, E., additional

Published
2019
Full Text
View/download PDF

50. Abstracts of posters

Author

Suffisseau L., Taugourdeau M. C., Goldstein F. W., Mainardi J. L., Larrouturou Ph., Romero, M., Cervino, A. R., Albertone, G., Di Pasquale, R., Venturini, F., Congedo, R., Benettolo, F., Pistolesi, C., Olivato, R., Casasin T., Agusti C., Gurrera M. T., Fabregas X., Rizo A., Badia J. M., Santa-Olalla M., Marini, P., Rampazzo, R., Scroccaro, G., Dell'Aera, M., Luzzi, R., Ciccarone, G., Martinet, N., Beney, J., Marty, S., Reymond, J. -Ph., Cairns, Chris, Morgutti M., Posco M., Moltempi M., Lonqhini P., Rossignoli A., Rihet, P., Carles, G., Braguer, D., Azulay, J. P., Pouget, J., Pelletier, J., Crevat, A., Past.o, L., Barroso, E., Pujol, R., Ferrer, I., Ibars, M., Llop, J. M., Frankfort, Ellen, van Dongen, Robert T. M., Hekster, Yechiel A., Kart, T., Rasmussen, M., Horn, A., Wested, L., Gagyi, O., Markó, E., Regazzi M. B., Martinelli L., Goggi C., Bellotti E., Molinaro M., Rinaldi M., Gavazzi A., Buggia I., Daneri A., Guarnone E., Bascapē V., Viganô M., Lazzaro, A., Palozzo, A., Banfi R., Borselli G., Fabbiani P., Marinai C., Delorme, J., Tubiana, N., Buck, M., Chinot, O., De Wever, C., Robays, H., Montoro J. B., Flores G., Juárez J. C., Juste C., Jardí R., Altisent C., Tusell J. M., Arpinelli, F., De Carli, G., Olivieri, A., Recchia, G., Rossignoli A., Longhini P., La Guidara C., Russo B., Moltempi M., Tamés, M. J., Cajaraville, G., Ponz, L., Echaniz, E., Garcia, B., van Mil, J. W. Foppe, Leufkens, Hubert G., v. Haelst, Ingrid M. M., Parel, Piet C. M., Scholten, Wim K., Sessink, F. G. M., Raschatt, R., Traversa, G., Donini, G., Arpino, C., Da Cas, R., Pasquin, P., Bernadotte af Wisborg G., Claesson C., Lundberg O., Thorslund M., Ferraro L., Marrazzo E., Ostino G., Tognoni G., Heerdink, Eibert R., Koppedraaijer, Corrie, Bakker, Albert, Bidoli E., Battistin M., Troncon M. G., Franceschi S., Serraino D., Marino, M., Matera, M. G., Berrino, L., Contaldi, C., Piucci, B., Rossi, F., Rolle C., Marrazzo E. 0., Murgia, V., Bussi, R., Schievano, P., Pedrini, A., Baraghini, M., Benini, A., Cataldo, M. M., Galletti, P., Magnani, M., Manzoli, M., Novi, M. V., Pezzi, O., Font M., Salmaso A. B., Mezzalira L., Braybrook, Saran, Walker, Roger, van Mil, J. W. F., Tromp, F. T. J., de Jong-v.d. Berg, L. T. W., Bakker, A., Paes, A. H. P., Soe-Agnie, C., Llopis, P., Tortajada, J. J., Font, I., Climente, M., Real, J. V., Almenar, D., Molins, C., Jiménez, N. V., Bellés Medall MD, Casterá Melchor DE, Marco Sena MA, Cantarinz Marti I., Abad Gimeno FJ, Török, J., Thurzó, L., Juárez J. C., Oliveras M., Hidalgo E., Cabañas M. J., Barroso C., Moraga F. A., Sánchez de Toledo J., Kollöffel, W. J., Driessen, F. G. W. H. M., Goldhoorn, P. B., Moral, M. A., Roglan, A., Mangues, M. A., Bonal, J., Clopés, A., Badell, I., Fraga, G., Deinum, J. T., van Lingen, R. A., Quak, J. M. E., Kuizenga, A. J., van Dam, J. G., Villani P., Maserati R., Viale P., Alberici F., Iacona I., Wasieczko, A., Szymura-Oleksiak, J., Wyska, E., Magulova, L., Sirotiakova, J., Letkovicova, M., Branger, E., Besse, D., Blin, O., Bille, F., Serratrice, G., Desnuelle, C., Grassin, J., Reben, I., Meunier, Ph., Antier, D., Berthet, M., Søndergaard B., Herborg H., Frøkjær B., Hepler C., Steckner, H., Bergold, A., Drings, P., Märkel, A., Manegold, C., Venning, Mary, Pazzagli, Luciana, Semmola, Maria Vittoria, Mannoni, Alessandro, Tersen I., Huchet J., Sevilla, E., Ferrari, J. M., Herreros de Tejada, A., Congedo, R., Font, M., Fraccaro, A., Osti, M., Pappagallo, G., Spolaor, A., Terrazzani, G., Vezzani, M., Edouard B., Laine G., Geeraerts D., Robays H., Carrera-Hueso, F. J., Font, B., Marquina, C., Idoate, A., Giráldez, J., Fernández, E., Lacasa, C., Guzzo, D., Martini, N., Boya, P. Giner, González, M. M. Negredo, Agulló, J. Muñoz, Mansilla, L. Lorente, Nahata, Milap C., Troncon, M. G., Cattaruzzi, C., Bilbao G., Galende I., Atañé C., Bermudez de Castro A., Delgado O., Escribano B., Frías J., Gabriel R., Gómez J. A., Gracia D., Gutiérrez E., Hellín T., Izquierdo J. L., Moreno A., Requena T., Sainz-Terreros M., Tejedor J. C., Torralba A., Vigil D., Scuffi, C., Trallori, G., Messori, A., Bardazzi, G., Bonanomi, A., Silvano, R., D'Albasio, G., Bardelli, F., Verona, Firenzee, Bardelli, F., Corrado, A., Ferriols R., Aleixander M. J., Garcia J., Faus M., Ibañez E., Alós M., Rinaldi, M., Pharmacy & Therapeutic Committee (Ps&TC), Collaborative Group, SIFO-Veneto Working Group on Clinical Trials, Working Group on the Elaboration of an Approval Conditions Document to certify the Clinical Trials Ethics Committees in the Autonomous Community of Madrid, and Area SIFO di Metanalisi

Published
1994
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results